Recent Updates
Recently added Catalysts
PODD Positive Sentiment Score: 70/100

Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026

Key Takeaway: Insulet Corporation announced it will report its financial results for the first quarter of 2026 on May 6, 2026. The announcement includes details about a conference call scheduled for the same day at 8:00 a.m. Eastern Time. The call will be accessible via the company's Investor Relations website and by phone for both domestic and international callers.
Price reaction · baseline $209.84 (2026-03-31 close) · hit after-hours · clean, no other PODD news in the window
day 0 close · peak
-1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Insulet is a leader in innovative insulin pump technology.
  • The Omnipod system offers a convenient alternative to traditional methods.
  • The upcoming financial results may indicate positive growth.

Full Press Release Details

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader intubeless insulin pump technologywith its Omnipod®brand of products, today announced it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time).
The link to the live call will be available on the Investor Relations section of the Company's website atinvestors.insulet.com, “Events and Presentations,” and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers; the passcode is 5904836.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit:insulet.comandomnipod.com.
©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.

Frequently Asked Questions

When will Insulet announce its Q1 2026 financial results?

Insulet will announce its Q1 2026 financial results on May 6, 2026.

What time is the conference call for the financial results?

The conference call will take place at 8:00 a.m. Eastern Time.

How can I access the conference call?

The conference call can be accessed via phone or through the Investor Relations website.

What is the Omnipod system?

The Omnipod system is an innovative insulin management platform by Insulet.

Last updated: Apr 1, 2026